DGAP-News

MOLOGEN AG: General Meeting votes in favour of all proposed resolutions and elects new Supervisory Board members

DGAP-News: MOLOGEN AG / Key word(s): AGM/EGM/Change of Personnel
MOLOGEN AG: General Meeting votes in favour of all proposed
resolutions and elects new Supervisory Board members

15.08.2014 / 09:45

---------------------------------------------------------------------

MOLOGEN AG: General Meeting votes in favour of all proposed resolutions and
elects new Supervisory Board members

Berlin, August 15, 2014 - At the Annual General Meeting of MOLOGEN AG on
August 13, 2014, the shareholders voted with a large majority in favour of
the proposals of the Management and Supervisory Board in all agenda items.
Essentially, it has been decided to create a new authorized capital and,
again, an employee options programme including the creation of a
corresponding new conditional capital. In addition, two new members of the
Supervisory Board have been elected on a regular cycle. The majority of the
General Meeting voted in favour of the two candidates that had been
proposed by the Supervisory Board: Oliver Krautscheid and Stefan M. Manth,
MD. The Supervisory Board elected unanimously Oliver Krautscheid as the new
Chairman and Stefan M. Manth, MD, as his deputy.

In total, around 69 per cent of the total voting share capital of MOLOGEN
AG was present at the Annual General Meeting.

Before the votes, the CEO Dr. Matthias Schroff and CFO Jörg Petraß
explained to the attending shareholders in particular the latest promising
advances of the main product candidate MGN1703. In addition, the achieved
advancement of the whole clinical pipeline, the economic situation of
MOLOGEN AG and the further strategic plans of the company were presented.

About MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immune therapies and DNA vaccines against
infectious diseases.

The cancer immune therapy MGN1703 is the company's lead product and
best-in-class TLR-9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
lung cancer (randomized trial). Second clinical-stage product is MGN1601, a
therapeutic vaccination for the treatment of renal cancer. A phase I/II
clinical study has already been completed successfully.

With unique, patented technologies and innovative products, MOLOGEN is
pioneering immune therapies.
MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200) are listed in the Prime Standard of the German
Stock Exchange.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |